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3Joshua Kays 
Distinct Cachexia Phenotypes and the Importance of Adipose Tissue Loss on Survival of 
Patients with Advanced Pancreatic Cancer on FOLFIRINOX Chemotherapy 
By the traditional definition of unintended weight loss, cachexia develops in 
~80% of patients with pancreatic ductal adenocarcinoma (PDAC). Here we measure the 
longitudinal body composition changes in patients with advanced PDAC undergoing 
FOLFIRINOX therapy. We performed a retrospective review of 53 patients with 
advanced PDAC on FOLFIRINOX as first line therapy at Indiana University Hospital 
from July 2010 to August 2015. Demographic, clinical, and survival data were collected. 
Body composition measurement, trend, univariate and multivariate analysis were 
performed. Three cachexia phenotypes were identified. The majority of patients, 64%, 
had Muscle-and-Fat Wasting (MFW), while 17% had Fat-Only Wasting (FW) and 19% 
had No Wasting (NW). NW had significantly improved overall median survival (OMS) 
of 22.6 months vs. 13.0 months for FW and 12.2 months for MFW (p=0.02). FW 
(HR=5.2; 95%CI=1.5-17.3) and MFW (HR=1.8; 95%CI=1.1-2.9) were associated with 
an increased risk of mortality compared to NW. OMS and risk of mortality did not differ 
between FW and MFW. Progression of disease, sarcopenic obesity at diagnosis, and 
primary tail tumors were also associated with decreased OMS. On multivariate analysis 
cachexia phenotype and chemotherapy response were independently associated with 
survival. Three phenotypes of cachexia were observed. Moreover, three phenotypes 
suggests molecular or genetic heterogeneity of host or tumor. Identifying these 
differences will be vital to defining optimal treatment for cachexia. Survival among FW 
was as poor as MFW suggesting adipose tissue plays a crucial role in cachexia. Blunting 
iii
4or possibly preventing cachexia may confer a significant survival advantage in patients 
with advanced PDAC.  
Teresa A. Zimmers, PhD, Chair 
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9Chapter One 
Introduction 
Pancreatic cancer is the fourth leading cause of cancer deaths in the United States 
and is on the rise (1). The ductal adenocarcinoma (PDAC) subtype accounts for the 
majority of cases of pancreatic cancer (1). Patients with PDAC typically present late with 
advanced, unresectable disease and have a dismal prognosis (2,3). Gemcitabine-based 
chemotherapy regimens have traditionally been the standard treatment protocol for 
unresectable PDAC. Unfortunately, most patients will not respond and overall median 
survival (OMS) is only 6-9 months (2,3).  
The chemotherapy combination of 5-fluorouracil, leucovorin, irinotecan, and 
oxaliplatin (FOLFIRIOX) has improved survival but the overall prognosis remains 
exceedingly grim. Recent studies have shown FOLFIRINOX to be superior to 
gemcitabine, however, OMS still only approaches 15 months (4-8). Furthermore 
FOLFIRINOX is often poorly tolerated and dosing may need to be reduced or completely 
discontinued due to severe side effects (5-9).  
Cachexia therapy represents a major unmet need in patients with unresectable 
PDAC. Cachexia is a complex metabolic derangement characterized by loss of muscle 
with or without the loss of fat that cannot be reversed by nutritional support (10). It has 
been associated with decreased tolerance of and response to treatment, decreased quality 
of life, decreased survival, and generally worse overall outcomes in patients with 
malignancies, including PDAC (10-13). The vast majority of patients with PDAC will 
develop cachexia during the course of their illness, even as early as at time of diagnosis, 
and cachexia has been implicated as a significant cause of death (14).  
1
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Body composition measurements obtained from computed tomography (CT) 
scans have emerged as a novel prognostic factor in many cancers, including PDAC (15-
18). These measurements can be used to detect low muscle mass, known as sarcopenia, 
and fatty muscle infiltration, known as myosteatosis. Sarcopenia, sarcopenic obesity, and 
myosteatosis have all been associated with decreased survival in patients with 
malignancy (19-22). CT scans are routinely obtained in patients with unresectable PDAC 
for staging and to monitor disease response to treatments. These CT scans are readily 
available and thus body composition measurements and changes represent a potentially 
crucial component in the prognostic and treatment equations for patients and provide an 
invaluable tool for researchers. 
Although the role of cachexia in PDAC is clear, to date there has been little work 
done to define the longitudinal development of cachexia in these patients and effort to 
understand the impact of FOLFIRINOX therapy on cachexia. Herein a longitudinal study 
of 53 patients with locally advanced and metastatic PDAC on FOLFIRINOX therapy was 
performed and changes in body composition and the effects on survival were examined. 
2
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Conversation 
This study examined the longitudinal changes in body composition and the 
associations of these changes with survival in patients with advanced PDAC undergoing 
FOLFIRINOX chemotherapy as first-line treatment. Using the traditional definition of 
>5% body weight loss to define cachexia, only 56.6% of patients in this cohort developed 
cachexia over the course of their disease. Using our definition of ≥5% loss of muscle 
and/or fat mass, the prevalence of cachexia was 81%. This is consistent with previously 
published data and provides further evidence that cachexia treatment is a major unmet 
need of patients with advanced PDAC (14). The study also identified three different 
cachexia phenotypes, No Wasting (NW), Fat-Only Wasting (FW), and Muscle and Fat 
Wasting (MFW). The study identifies a subset of patients, NW, who appear resistant to 
cachexia and as a result have significantly improved survival. In addition, the study 
showed fat loss to be an equally important factor on survival as muscle loss. 
To the best of the authors’ knowledge this is the first paper to demonstrate 
different wasting patterns in patients with any cancer or chronic disease. The 
identification of these phenotypes is a critical detail as it suggests molecular and/or 
genetic heterogeneity among the hosts or the tumors as the driving force for each wasting 
pattern. Several cytokines have been proposed to be vital to the development of cachexia, 
including tumor necrosis factor-alpha, interleukin-1, interleukin-6 (IL-6), interferon-
gamma, ciliary neurotrophic factor, and myostatin (23-29). It has been shown that 
nucleotide polymorphisms in genes that are linked to production rates are associated with 
the development of cachexia (30), specifically in regards to IL-6 in the setting of 
pancreatic cancer (31). While this study does not demonstrate molecular or genetic 
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differences, the distinct phenotypes are highly suggestive. Additional studies focusing on 
molecular and genetic difference of PDAC tumors and the patients are indicated, as 
therapies targeting the precise cause of cachexia are essential to achieve optimal 
outcomes.  
The second major finding of this study is the lack of difference in survival 
between patients who lost muscle and fat and patients who lost only fat. The prominent 
theory in cachexia is that muscle loss is the major complication in cancer cachexia and to 
date cachexia research has mainly focused on muscle. The data presented here suggests 
that fat has an equivalent role, as developing the FW phenotype conferred a decreased 
survival that was not significantly different than the MFW phenotype.  
Adipose tissue has long been seen as an energy regulating tissue with additional 
responsibilities of mechanical protection and temperature regulation. This changed with 
the discovery of leptin production by adipose tissue and it was recognized that fat had 
important endocrine functions as well (32). Since this discovery, adipose tissue has been 
shown to express and secret a number of different signaling molecules including the 
cachexia-associated cytokines TNF-α and IL-6 (33). The loss of adipose tissue in cancer 
cachexia has also been shown to be accompanied by changes in gene expression 
pathways regulating energy turnover (34). Although it has been shown that fat loss is 
associated with decreased survival in patients with PDAC (35), the data here shows that 
fat loss appears to be equivalent to muscle loss.      
Previous studies have shown sarcopenia, sarcopenic obesity, and myosteatosis to 
be associated with decreased survival in pancreatic cancer (20-22). Of these variables, 
only sarcopenic obesity was shown to be associated with survival and it did not hold up 
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in multivariate analysis (Table 3). While not statistically significant, all of these variables 
did trend in the direction of having an impact on survival. In a large patient cohort these 
variables would likely show statistical significance and be in line with previously 
published data. 
This study also gives insight into how we should be defining cachexia. The 
prevalence of cachexia defined by the traditional definition of >5% body weight loss was 
only 56.6%, while the prevalence using the study’s definition of ≥5% loss of muscle or 
fat mass was 81%. The study’s definition is more in line with previously published data 
(14). No patient in the NW phenotype had >5% body weight loss. However, applying that 
definition to the FW and MFW phenotypes would have caused 5/9 and 25/34 patients to 
be classified as developing cachexia. This would have missed 13/43, or 30%, or patients 
with significant muscle or fat wasting. One explanation would be that patients with 
advanced PDAC are prone to developing ascites, and the ascites is contributing to 
maintenance of body weight despite the fact that significant muscle and/or fat wasting is 
occurring. Using CT body morphometric measurements is a more accurate way of 
determining a patient’s cachexia status. 
The current study is not without limitations. It is a retrospective study and 
therefore is subject to all limitations associated with retrospective studies. The Eastern 
Cooperative Oncology Group (ECOG) score was not available. Patients who are eligible 
for FOLFIRINOX therapy are high functioning patients with ECOG scores of 0 or 1 and 
therefore it can be safely assumed that there was no difference in underlying functional 
status between any groups analyzed. This analysis was also performed on an intent to 
treat basis. Data on changes to the chemotherapy regimens such as dose reductions or 
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changes in medications that could possibly have altered the patients’ course were not 
available. Additionally, co-morbidities were not available and the authors recognize that 
some patients may have had significant co-morbidities that contributed to the outcome.   
The study evaluated only 53 patients and this may have limited the study’s power 
to detect the effects of some variables. While this is enough patients to safely say that the 
differences found are truly present, the authors recognize that it is not enough power to 
adequately eliminate type II error and that differences may be present that were not 
detected.  
All patients in the current study presented with advanced PDAC. Given the high 
rate of development of cachexia in these patients it can be safely assumed that the initial 
CT scan was obtained after some degree of cachexia developed. The authors do not 
believe this would have an effect on the overall results. Closer examination of the NW 
phenotype shows all the patients had significant increase in muscle, fat, or both tissues 
during the course of treatment thus establishing a cachexia-resistant phenotype. The FW 
phenotype presented with lower SKMI and this is possibly due to muscle wasting 
occurring before the initial scan. This group, however, did not lose any additional muscle 
throughout the course of the disease, while the MFW phenotype lost muscle and fat 
congruently. Therefore, we can safely conclude that these are also two distinct 
phenotypes of cachexia.  
This study is susceptible to length time bias. This is an unavoidable bias as there 
is no accurate screening test for PDAC and there is no way to know exactly when the 
6
15
disease process began. Analysis of days to diagnosis of cachexia showed no difference 
between FW and MFW (p=0.67).  
Finally, this study only applies to patients who received FOLFIRINOX as first-
line treatment. It has previously been shown that certain chemotherapy regiments can 
induce cachexia alone (36). To the best of the authors’ knowledge there is no data linking 
the administration of FOLFIRINOX to the development of cachexia. It has, however, 
been shown that cachexia develops in the vast majority of patients with PDAC (14). Thus 
it is unlikely that FOLFIRINOX was solely responsible for the cachexia that was 
observed. Additionally, the NW phenotype patients also received FOLFIRINOX. This 
strengthens the conclusion that the cachexia was disease driven and not treatment driven. 
Nevertheless, similar studies need to be performed involving patients undergoing other 
chemotherapy regiments and in other malignancies before these results can be 
generalized.  
To the best of the authors’ knowledge, this is the first study to show distinct 
cachexia phenotypes in any cancer or chronic disease. The fact that multiple phenotypes 
emerged raises suspicion that molecular and/or genetic heterogeneity is present in the 
hosts or the tumors and discovery of these differences could lead to more targeted 
therapies. Individualized therapy will be crucial in order to optimize care of patients with 
cachexia. The study also demonstrates the important role that adipose tissue plays in 
cachexia. Research focusing on fat’s role in cachexia will be vital to understanding the 
entire disease process.  
7
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Chapter Two 
Methods 
This study was approved by the Indiana University Institutional Review Board 
and was carried out in compliance with the IU Standard Operating Procedures for 
Research Involving Human Subjects. All data collection occurred between September 1, 
2015 and November 29, 2016.  
All patients presenting to Indiana University Hospital between the dates of July 1, 
2010 and August 31, 2015 with advanced PDAC treated with FOLFIRINOX as first-line 
therapy with available survival data and adequate CT images for analysis were eligible 
for inclusion in the study. Advanced PDAC was defined as PDAC that was not 
amendable to surgical resection. Sixty-six patients were identified. Upon review 13 
patients were excluded: four with missing CT scans, six with only a single CT scan, two 
with poor quality CT scans unable to be analyzed, and one treated with an alternative 
chemotherapy regimen prior to presentation at Indiana University. This resulted in 53 
total subjects in the study. Demographic, clinical, and survival data along with CT scans 
were collected on these 53 subjects. 
CT images were analyzed for cross-sectional area (cm2) for skeletal muscle 
(SKM), intramuscular adipose tissue (IMAT), visceral adipose tissue (VAT), and 
subcutaneous adipose tissue (SCAT) mass at the level of the 3rd lumbar vertebrae (L3) 
(37) using Slice-O-Matic® software V4.3 (Tomovision, Montreal, Quebec, 
Canada)(Figure 1). Hounsfield unit thresholds were set at -29 to +150 HU for SKM, -30 
to -190 HU for IMAT and SCAT, and -50 to -150 HU for VAT (38). Two consecutive 
images were analyzed on all CT scans by a single investigator (JKK). The mean of the 
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two images was normalized to height in meters-squared to establish tissue specific 
indices. Total adipose index (TAI) was calculated by adding IMAT index (IMATI), VAT 
index (VATI) and SCAT index (SCATI). Sarcopenia was defined as a SKMI <52.4 
cm2/m2 for males and <38.5 cm2/m2 for females (19). Myosteatosis was defined as a 
mean skeletal muscle radiodensity of <33 HU for patients with a BMI ≥25 kg/m2 and <41 
HU for patients with a BMI <25 kg/m2 (39).  Estimates of whole body stores for skeletal 
muscle, total adipose, and each adipose compartment were obtained by applying the 
following regression equations by Mourtzakis et al (25).  
Obesity was defined by the World Health Organization (WHO) criteria (40). Patients 
were classified as having sarcopenic obesity if they met the criteria for sarcopenia and 
obesity. Total muscle measurements included the rectus abdominus, external and internal 
oblique, transversus abdominus, psoas, erector spinae, and quadratus lumborum. 
Disease response to chemotherapy was determined by using Response Evaluation 
Criteria in Solid Tumors (RECIST) criteria (41) by a single investigator (SS). Patients 
were classified into three groups based on best response: regression of disease, stable 
disease, and progression of disease. 
Serial CT scans were performed every three months per institution protocol. All 
CT scans from the time of diagnosis until the end of the study were analyzed and 
included in the data analysis. A total of 298 CT scans were analyzed. Tissue mass 
measurements were graphed versus time to identify any trends. Trends in skeletal muscle 
index (SKMI) and TAI were noted and patients were divided into three categories: No 
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Wasting (NW), Fat-Only Wasting (FW), and Muscle and Fat Wasting (MFW). Cut offs 
for significant change was set at ≥ 5% increase or decrease from the initial CT 
measurement to the final CT measurement. The subjects were then re-categorized as 
needed based on this cutoff threshold. Patients with a significant increase in one category 
but significant decrease in another category were defined as NW. 
Figure 1. Representative Slice-O-Matic Example. The left image is representative of a CT 
image at the L3 level as obtained during routine monitoring of the disease. The right 
image is the same CT image at the L3 level with the Slice-O-Matic tag overlay. Red 
represents skeletal muscle, yellow represents visceral adipose tissue, green represents 
intramuscular adipose tissue and blue represents subcutaneous adipose tissue. ive Slice-
O-Matic Example. The left image is representative of a CT  
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Statistical Analysis 
The primary outcome measure was overall survival, calculated in months from the 
time of diagnosis to the time of death or last follow up. The main prognostic factor was 
cachexia phenotype, however, age, sex, disease extent, best chemotherapy response, 
presence of sarcopenia, obesity, sarcopenic obesity, and myosteatosis at diagnosis, and 
tumor location were also examined. Age was dichotomized at the mean for Kaplan-Meier 
and Cox proportional analysis. Results of Kaplan-Meier survival analysis are reported as 
median survival with log base p values. Results of Cox proportional analysis are reported 
as hazard ratios with 95% confidence intervals.  
Mean age, BMI, tissue indices, changes in tissue indices, Hounsfield units, total 
number of CT scans, and months between initial and final CT scan were compared 
between cachexia phenotypes using ANOVA. Tukey’s method was performed when the 
ANOVA revealed a difference to identify where the difference occurred. Changes in 
BMI, tissue indices, and Hounsfield units were analyzed by one-sample T test to evaluate 
for difference from zero. Sex, disease extent, disease response, tumor location, obesity, 
sarcopenia, sarcopenic obesity and myosteatosis were compared between cachexia 
phenotypes using Pearson’s chi-square test. All continuous variables are reported as the 
mean with standard deviation, with the exception of total number of CT scans and 
months between initial and final CT scan, which are reported with the range. All 
categorical variables are reported as the true measurement with percentage. 
Multivariate analysis was performed using generalized linear regression. All 
variables were included in the multivariate analysis except sarcopenia and obesity. Age 
was dichotomized at the mean for multivariate analysis. Results are reported as difference 
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in months of survival compared to the stated reference with 95% confidence intervals and 
p values. 
All statistical analysis was performed using IBM SPSS Statistics for Windows 
version 23.0 (SPSS, Chicago, IL). Images for Kaplan-Meier curves and tissue trend 
graphs were created using GraphPad Prism version 7 (GraphPad Software, LaJolla, CA). 
Waterfall plots were created using Microsoft Excel for Windows 2016 (Microsoft 
Corporation, Redman, WA). Significance was set at a p value < 0.05 for all results. 
1
21
Results 
Demographic and disease data are summarized in Table 1. Overall mean age was 
59.5 (SD=9.9) years. The majority of the patients were male, 62.3%. Patients presented 
equally with locally advanced and metastatic diseae, 49% and 51% respectively. The 
majority of patients had positive response to chemotherapy with 43% having tumor 
regression and 40% having stable disease compared to 17% with tumor progression. The 
pancreatic head (51%) was the most common place for the primary tumor followed by 
the body (38%) then the tail (11%). Overall patients were less likely to be obese (44%) or 
have sarcopenic obesity (11%) and equally likely to have sarcopenia (49%) at 
presentation. A total of 296 CT scans were analyzed for an overall mean of 5.6 
(range=2.0-18.0) scans per subject. Mean time between initial CT scan and final CT scan 
analyzed was 11.1 months. Overall median survival was 14.7 months for the entire cohort 
(Figure 2A). History of weight loss prior to presentation was unknown.  
Based on SKMI and TAI trend analysis (Figure 3) three distinct wasting patterns 
were identified: The majority of patients developed MFW, 64%, followed by NW, 19%, 
and FW, 17%. The was no difference between phenotypes in age, sex, disease extent, 
disease response, tumor location, obesity, sarcopenia, myosteatosis, mean number of CT 
scans or time between CT scan. Sarcopenic obesity was more likely to be present in the 
FW phenotype.  
Initial body composition measurements and changes are summarized in Table 2. 
There was no difference in initial BMI, IMATI, VATI, SCATI, or TAI. A difference was 
observed in initial SKMI and SKM HU between the groups (p=0.036 and p=0.045). Post-
hoc analysis revealed the FW phenotype started with lower SKMI and SKM HU 
13
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measurements than the MFW phenotype. Figure 4 illustrates the tissue changes for each 
patient. The NW phenotype showed no significant losses in any measured variable and 
actually showed significant increases in BMI, IMAT, SCAT, and TAI. The FW 
phenotype showed significant losses in all adipose tissue compartments and in total 
adipose tissue. The MFW phenotype showed significant losses in all measured variables 
including SKM HU.  
Univariate analysis showed that cachexia phenotype, chemotherapy response, and 
tumor location were associated with survival. FW phenotype had an OMS of which was 
significantly longer than FW and MFW (Figure 2B). FW and MFW were associated with 
an increased of mortality when compared to NW (Table 3). Presence of sarcopenic 
obesity on initial CT scan was associated with a significantly decreased OMS (Figure 
2C). Other variables associated with decreased OMS and increased risk of mortality were 
progression of disease while on FOLFIRINOX therapy and primary tumors located in the 
tail of the pancreas (Table 3).  
Multivariate analysis showed cachexia phenotype, chemotherapy response, and 
tumor location to be independently associated with overall survival. Development of FW 
is associated with a mean decrease in survival of 9.9 months while development of MFW 
is associated with a mean decrease in survival of 8.8 months when compared to NW. 
Progression of disease while on FOLFIRINOX was associated with a mean decrease in 
survival of 7.0 months when compared with regression of disease (Table 3). 
Median time to onset of cachexia was 71.5 days. Comparing survival of patients 
who had early onset cachexia, before the median, and those that had late onset cachexia, 
14
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after the median, showed no difference, 16.1 vs. 12.2 months (p=0.88), or risk of 
mortality (HR=1.06; 95%CI=0.50-2.24). 
Table 1. Patient Characteristics (N=53) 
Variable Overall NW 
(19%) 
FW (17%) MFW 
(64%) 
P Value 
Age, years (SD) 59.5 (9.9) 58.8 (7.7) 61.0 (12.4) 59.4 (10.0) 0.88 
Sex 
   Male 
   Female 
33 
20 
7 
3 
5 
4 
13 
21 
0.81 
Disease Extent 
   Locally Advanced 
   Metastatic 
26 
27 
3 
7 
6 
3 
17 
17 
0.28 
Disease Response 
   Regression 
   Stable 
   Progression 
23 
21 
9 
6 
2 
2 
5 
3 
1 
12 
16 
6 
0.52 
Tumor Location 
   Head 
   Body 
   Tail 
27 
20 
6 
2 
6 
2 
6 
3 
0 
19 
11 
4 
0.22 
Obesity at Dx 
   Yes 
   No 
18 
35 
2 
8 
4 
5 
12 
22 
0.51 
Sarcopenia at Dx 
   Yes 
   No 
26 
27 
5 
5 
7 
2 
14 
20 
0.15 
Sarcopenic Obesity 
   Yes 
   No 
6 
47 
0 
10 
4 
5 
2 
32 
0.002 
Myosteatosis 
   Yes 
   No 
28 
25 
6 
4 
7 
2 
15 
19 
0.18 
Mean # CT scans 
(range) 
5.6 (2-18) 6.9 (2-
18) 
4.2 (2-7) 5.6 (2-13) 0.21 
Mean Months 
between initial and 
final CT scan (range) 
11.1 (0.7 -
45-6) 
13.1 (6.7-
24.7) 
11.2 (0.9-
45.6) 
10.5 (0.7-
28.2) 
0.71 
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Figure 2. Kaplan-Meier Survival Curves. A) Overall median survival for the entire 
cohort was 14.7 months. B) Patients with NW had significantly increased median 
overall survival of 22.6 months compared to those with FW and MFW with median 
overall survivals of 13.0 and 12.2 months, respectively. C) Absence of sarcopenia on 
initial CT scan did not result in statistically significant increased survival compared 
to sarcopenia being present on initial CT scan, 17.0 and 13.0 months respectively.  
A)
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Figure 4. Muscle and Adipose Changes by Cachexia Phenotype. NW phenotype had 
nonsignificant loss of muscle or fat and most actually gain muscle and/or fat, while 
the FW group shows loss of only fat and the MFW shows major loss of muscle and 
fat when measured as kilograms (A) and as percent of initial measurement (B).  
20
2Chapter Three 
Conclusion 
Cachexia has been associated with decreased response and tolerance to therapy 
and decreased survival in patients with cancer. This study identifies three distinct 
cachexia phenotypes that are present in patients with advanced PDAC undergoing 
FOLFIRINOX therapy. The data demonstrates that there is a subset of patients that are 
resistant to cachexia, the NW group, and that this resistance confers a survival advantage. 
Additionally, the data shows no difference in survival between patients who lose only 
adipose tissue, FW, and those that lose muscle and adipose tissue, MFW, suggesting 
adipose tissue plays a crucial role in cachexia. Three phenotypes suggests molecular or 
genetic heterogeneity of the host or tumor and identifying these differences will be vital 
to defining optimal treatment for cachexia. Blunting or possibly preventing cachexia may 
confer a significant survival advantage in patients with advanced PDAC. 
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